ALT 0.00% 0.5¢ analytica limited

New article, page-3

  1. 23,832 Posts.
    lightbulb Created with Sketch. 725
    So we have done a deal with the WA government, yet management couldn't find a way to confirm it to the market - IMO that is a massive precursor to multi-state roll out and should be announced, but hasn't for whatever commercial reasons

    Now the FDA are giving pelvic mesh the big No No and have even cited ALT's PeriCoach

    "FDA recommends that women be aware of the risks associated with surgical mesh. On an advice page on the FDA website, the agency writes: "Ask your surgeon about all POP treatment options, including surgical repair with or without mesh and non-surgical options."

    Non-surgical options include pelvic floor exercises known as Kegels. There are also non-invasive devices such as the PeriCoach, a smartphone-connected pelvic floor muscle training device for incontinence."

    They need to work on their marketing, as that is 2 nice scores for them and neither has been communicated to the market by them

    One could be forgiven for thinking that perhaps they want those February options to expire first ?
 
watchlist Created with Sketch. Add ALT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.